1. Home
  2. NVRO vs RZLT Comparison

NVRO vs RZLT Comparison

Compare NVRO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVRO
  • RZLT
  • Stock Information
  • Founded
  • NVRO 2006
  • RZLT 2010
  • Country
  • NVRO United States
  • RZLT United States
  • Employees
  • NVRO N/A
  • RZLT N/A
  • Industry
  • NVRO Medical/Dental Instruments
  • RZLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVRO Health Care
  • RZLT Health Care
  • Exchange
  • NVRO Nasdaq
  • RZLT Nasdaq
  • Market Cap
  • NVRO N/A
  • RZLT 303.1M
  • IPO Year
  • NVRO 2014
  • RZLT N/A
  • Fundamental
  • Price
  • NVRO $5.53
  • RZLT $5.52
  • Analyst Decision
  • NVRO Hold
  • RZLT Strong Buy
  • Analyst Count
  • NVRO 14
  • RZLT 7
  • Target Price
  • NVRO $9.80
  • RZLT $11.57
  • AVG Volume (30 Days)
  • NVRO 315.8K
  • RZLT 378.1K
  • Earning Date
  • NVRO 11-11-2024
  • RZLT 11-11-2024
  • Dividend Yield
  • NVRO N/A
  • RZLT N/A
  • EPS Growth
  • NVRO N/A
  • RZLT N/A
  • EPS
  • NVRO N/A
  • RZLT N/A
  • Revenue
  • NVRO $426,098,000.00
  • RZLT N/A
  • Revenue This Year
  • NVRO N/A
  • RZLT N/A
  • Revenue Next Year
  • NVRO $2.58
  • RZLT N/A
  • P/E Ratio
  • NVRO N/A
  • RZLT N/A
  • Revenue Growth
  • NVRO 1.59
  • RZLT N/A
  • 52 Week Low
  • NVRO $4.38
  • RZLT $0.72
  • 52 Week High
  • NVRO $22.64
  • RZLT $6.10
  • Technical
  • Relative Strength Index (RSI)
  • NVRO 57.13
  • RZLT 59.19
  • Support Level
  • NVRO $4.53
  • RZLT $5.23
  • Resistance Level
  • NVRO $5.67
  • RZLT $5.93
  • Average True Range (ATR)
  • NVRO 0.33
  • RZLT 0.31
  • MACD
  • NVRO 0.10
  • RZLT 0.04
  • Stochastic Oscillator
  • NVRO 84.75
  • RZLT 61.27

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Share on Social Networks: